USA Pediatric Proton Therapy Market, Patient Numbers, Forecast By Age & Tumors (36 Cancer Types Analyzed)

1.    Research Findings

2.    United States Pediatric Proton Therapy Market (Actual & Potential)
2.1    United States Pediatric Proton Therapy Market & Forecast

2.2    United States Potential Pediatric Proton Therapy Market & Forecast

3.    USA Pediatric Proton Therapy Market by Age Group
3.1    By Age Group (<1) Year

3.2    By Age Group (1-4) Year

3.3    By Age Group (5-9) Year

3.4    By Age Group (10-14) Year

3.5    By Age Group (15-18) Year

4.    USA Pediatric Proton Therapy Patient Number - Actual and Potential
4.1    USA Pediatric Patients Treated with Proton Therapy Actual Numbers & Forecast

4.2    United States – Pediatric Patients with Proton Therapy Potential Numbers & Forecast

5.    USA Pediatric Proton Therapy Patients Numbers by Age Group
5.1    By Age (<1) Year

5.2    By Age (1- 4) Year

5.3    By Age (5- 9) Year

5.4    By Age (10-14) Year

5.5    By Age (15- 18) Year

6.    Tumor Types – USA Pediatrics Proton Therapy Market (2010 – 2021)
6.1    Glioma, Low Grade – Market & Forecast

6.2    Glioma, High Grade – Market & Forecast

6.3    Medulloblastoma – Market & Forecast

6.4    Ependymoma – Market & Forecast

6.5    ATRT – Market & Forecast

6.6    Germinoma, Pure – Market & Forecast

6.7    Germ Cell Tumor – Market & Forecast

6.8    Craniopharyngioma – Market & Forecast

6.9    PNET – Market & Forecast

6.10    Pineoblastoma – Market & Forecast

6.11    Chordoma/Chondrosarcoma – Market & Forecast

6.12    Meningioma – Market & Forecast

6.13    AVM – Market & Forecast

6.14    Adenoma – Market & Forecast

6.15    Choroid Plexus Carcinoma – Market & Forecast

6.16    Retinoblastoma – Market & Forecast

6.17    Osteosarcoma – Market & Forecast

6.18    Ewing Sarcoma – Market & Forecast

6.19    Rhabdomyosarcoma – Market & Forecast

6.20    Other Sarcoma, High Grade – Market & Forecast

6.21    Other Sarcoma, Low Grade – Market & Forecast

6.22    Teratoma – Market & Forecast

6.23    Neuroblastoma – Market & Forecast

6.24    Ganglioglioma – Market & Forecast

6.25    Wilm’s Tumor – Market & Forecast

6.26    Carcinoma (non-CPC) – Market & Forecast

6.27    Lymphoma, Hodgkin’s – Market & Forecast

6.28    Lymphoma, Non-hodgkin’s – Market & Forecast

6.29    Leukemia – Market & Forecast

6.30    Desmoid – Market & Forecast

6.31    Melanoma – Market & Forecast

6.32    Pineal Parenchymal Tumor – Market & Forecast

6.33    Esthesioneuroblastoma – Market & Forecast

6.34    Angiofibroma – Market & Forecast

6.35    Extrarenal Rhabdoid Tumor – Market & Forecast

6.36    Others – Market & Forecast

7.    Tumor Types – United States Pediatrics Proton Therapy Patients (2010 – 2021)
7.1    Glioma, Low Grade – Patient Numbers & Forecast

7.2    Glioma, High Grade - Patient Numbers & Forecast

7.3    Medulloblastoma - Patient Numbers & Forecast

7.4    Ependymoma - Patient Numbers & Forecast

7.5    ATRT - Patient Numbers & Forecast

7.6    Germinoma, pure - Patient Numbers & Forecast

7.7    Germ Cell Tumor - Patient Numbers & Forecast

7.8    Craniopharyngioma - Patient Numbers & Forecast

7.9    PNET - Patient Numbers & Forecast

7.10    Pineoblastoma - Patient Numbers & Forecast

7.11    Chordoma/Chondrosarcoma - Patient Numbers & Forecast

7.12    Meningioma - Patient Numbers & Forecast

7.13    AVM - Patient Numbers & Forecast

7.14    Adenoma - Patient Numbers & Forecast

7.15    Choroid Plexus Carcinoma - Patient Numbers & Forecast

7.16    Retinoblastoma - Patient Numbers & Forecast

7.17    Osteosarcoma - Patient Numbers & Forecast

7.18    Ewing Sarcoma - Patient Numbers & Forecast

7.19    Rhabdomyosarcoma - Patient Numbers & Forecast

7.20    Other Sarcoma, High Grade - Patient Numbers & Forecast

7.21    Other Sarcoma, Low Grade - Patient Numbers & Forecast

7.22    Teratoma - Patient Numbers & Forecast

7.23    Neuroblastoma - Patient Numbers & Forecast

7.24    Ganglioglioma - Patient Numbers & Forecast

7.25    Wilm’s Tumor - Patient Numbers & Forecast

7.26    Carcinoma (non-CPC) - Patient Numbers & Forecast

7.27    Lymphoma, Hodgkin’s - Patient Numbers & Forecast

7.28    Lymphoma, Non-hodgkin’s - Patient Numbers & Forecast

7.29    Leukemia - Patient Numbers & Forecast

7.30    Desmoid - Patient Numbers & Forecast

7.31    Melanoma - Patient Numbers & Forecast

7.32    Pineal Parenchymal Tumor - Patient Numbers & Forecast

7.33    Esthesioneuroblastoma - Patient Numbers & Forecast

7.34    Angiofibroma - Patient Numbers & Forecast

7.35    Extrarenal Rhabdoid Tumor - Patient Numbers & Forecast

7.36    Others - Patient Numbers & Forecast

8.    Components of a Standard Proton Therapy Center
8.1    Proton Accelerator
8.1.1    Synchrotrons (example: LLUMC at Loma Linda)
8.1.2    Cyclotrons (example: MGH Boston)
8.1.3    Synchrocyclotrons (examples: Orsay, Uppsala)
8.1.4    H-minus Synchrotrons
8.1.5    Separated Sector Cyclotrons
8.1.6    Super-conducting Cyclotrons
8.1.7    Fast Cycling Synchrotron

8.2    Beam Transport System

8.3    Beam Delivery System
8.3.1    The Passive Scattering Technique
8.3.2    Beam Scanning

8.4    Nozzle
8.4.1    Single Scattering
8.4.2    Double Scattering
8.4.3    Uniform Scanning Nozzle
8.4.4    Pencil Scanning Nozzle

8.5    Treatment Planning System

8.6    Image Viewers

8.7    Patient Positioning System (PPS)

8.8    Human Resource

9.    Proton Therapy – Driving Factors
9.1    Technology Advancement

9.2    Rising Prevalence of Pediatric Cancer Patients in United States

10.    Proton Therapy – Challenges
10.1    Requires Huge Investment

10.2    Operations Challenges

11.    Global Proton Therapy - Company Analysis (2010-2021)
11.1    IBA Proton Therapy
11.1.1    Sales Analysis
11.1.2    IBA List of Proton Therapy Centers

11.2    Varian Medical Systems
11.2.1    Sales Analysis

11.3    Mitsubishi Electric Corporation
11.3.1    Sales Analysis
11.3.2    Mitsubishi List of Proton Therapy Center

11.4    Hitachi
11.4.1    Sales Analysis
11.4.2    Hitachi List of Proton Therapy Center

12.    Proton Therapy – Reimbursement Policies
12.1    Proton Therapy Reimbursement Policies for Patients

12.2    Proton Therapy Reimbursement for Institutions, Stakeholders and Manufacturers

List of Figures

Figure 2‑1: United States – Pediatric Proton Therapy Market (Million US$), 2010 – 2016
Figure 2‑2: United States – Forecast for Pediatric Proton Therapy Market (Million US$), 2017 – 2021
Figure 2‑3: United States – Potential Pediatric Proton Therapy Market (Million US$), 2010 – 2016
Figure 2‑4: United States – Forecast for Potential Pediatric Proton Therapy Market (Million US$), 2017 – 2021

Figure 3‑1: United States – Pediatric Proton Therapy Market by Age Group (<1) (Million US$), 2010 – 2016
Figure 3‑2: United States – Forecast for Pediatric Proton Therapy Market by Age Group (<1) (Million US$), 2017 – 2021
Figure 3‑3: United States – Pediatric Proton Therapy Market by Age Group (1-4) (Million US$), 2010 – 2016
Figure 3‑4: United States – Forecast for Pediatric Proton Therapy Market by Age Group (1-4) (Million US$), 2017 – 2021
Figure 3‑5: United States – Pediatric Proton Therapy Market by Age Group (5-9) (Million US$), 2010 – 2016
Figure 3‑6: United States – Forecast for Pediatric Proton Therapy Market by Age Group (5-9) (Million US$), 2017 – 2021
Figure 3‑7: United States – Pediatric Proton Therapy Market by Age Group (10-14) (Million US$), 2010 – 2016
Figure 3‑8: United States – Forecast for Pediatric Proton Therapy Market by Age Group (10-14) (Million US$), 2017 – 2021
Figure 3‑9: United States – Pediatric Proton Therapy Market by Age Group (15-18) (Million US$), 2010 – 2016
Figure 3‑10: United States – Forecast for Pediatric Proton Therapy Market by Age Group (15-18) (Million US$), 2017 – 2021

Figure 4‑1: United States – Pediatric Proton Therapy Patients (Number), 2010 – 2016
Figure 4‑2: United States – Forecast for Pediatric Proton Therapy Patients (Number), 2017 – 2021
Figure 4‑3: United States – Potential Pediatric Proton Therapy Patients (Number), 2010 – 2016
Figure 4‑4: United States – Forecast for Potential Pediatric Proton Therapy Patients (Number), 2017 – 2021

Figure 5‑1: United States – Pediatric Proton Therapy Patients by Age Group (<1) (Number), 2010 – 2016
Figure 5‑2: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (<1) (Number), 2017 – 2021
Figure 5‑3: United States – Pediatric Proton Therapy Patients by Age Group (1-4) (Number), 2010 – 2016
Figure 5‑4: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (1-4) (Number), 2017 – 2021
Figure 5‑5: United States – Pediatric Proton Therapy Patients by Age Group (5-9) (Number), 2010 – 2016
Figure 5‑6: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (5-9) (Number), 2017 – 2021
Figure 5‑7: United States – Pediatric Proton Therapy Patients by Age Group (10-14) (Number), 2010 – 2016
Figure 5‑8: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (10-14) (Number), 2017 – 2021
Figure 5‑9: United States – Pediatric Proton Therapy Patients by Age Group (15-18) (Number), 2010 – 2016
Figure 5‑10: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (15-18) (Number), 2017 – 2021

Figure 6‑1: United States – Glioma, Low Grade Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑2: United States – Forecast for Glioma, Low Grade Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑3: United States – Glioma, High Grade Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑4: United States – Forecast for Glioma, High Grade Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑5: United States – Medulloblastoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑6: United States – Forecast for Medulloblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑7: United States – Ependymoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑8: United States – Forecast for Ependymoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑9: United States – ATRT Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑10: United States – Forecast for ATRT Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑11: United States – Germinoma, Pure Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑12: United States – Forecast for Germinoma, Pure Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑13: United States – Germ Cell Tumor Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑14: United States – Forecast for Germ Cell Tumor Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑15: United States – Craniopharyngioma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑16: United States – Forecast for Craniopharyngioma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑17: United States – PNET Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑18: United States – Forecast for PNET Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑19: United States – Pineoblastoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑20: United States – Forecast for Pineoblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑21: United States – Chordoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑22: United States – Forecast for Chordoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑23: United States – Meningioma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑24: United States – Forecast for Meningioma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑25: United States – AVM Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑26: United States – Forecast for AVM Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑27: United States – Adenoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑28: United States – Forecast for Adenoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑29: United States – Choroid Plexus Carcinoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑30: United States – Forecast for Choroid Plexus Carcinoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑31: United States – Retinoblastoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑32: United States – Forecast for Retinoblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑33: United States – Osteosarcoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑34: United States – Forecast for Osteosarcoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑35: United States – Ewing Sarcoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑36: United States – Forecast for Ewing sarcoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑37: United States – Rhabdomyosarcoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑38: United States – Forecast for Rhabdomyosarcoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑39: United States – Other Sarcoma, High Grade Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑40: United States – Forecast for Other Sarcoma, High Grade Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑41: United States – Other Sarcoma, Low Grade Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑42: United States – Forecast for Other Sarcoma, Low Grade Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑43: United States – Teratoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑44: United States – Forecast for Teratoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑45: United States – Neuroblastoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑46: United States – Forecast for Neuroblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑47: United States – Ganglioglioma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑48: United States – forecast for Ganglioglioma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑49: United States – Wilms tumor Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑50: United States – Forecast for Wilms tumor Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑51: United States – Carcinoma (non-CPC) Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑52: United States – Forecast for Carcinoma (non-CPC) Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑53: United States – Hodgkin's Lymphoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑54: United States – Forecast for Hodgkin's Lymphoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑55: United States – Non-Hodgkin Lymphoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑56: United States – Forecast for Non-Hodgkin Lymphoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑57: United States – Leukemia Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑58: United States – Forecast for Leukemia Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑59: United States – Desmoid Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑60: United States – Forecast for Desmoid Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑61: United States – Melanoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
Figure 6‑62: United States – Forecast for Melanoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑63: United States – Pediatric Proton Therapy Market for Pineal Parenchymal Tumor (Thousand US$), 2010 – 2016
Figure 6‑64: United States – Forecast for Pediatric Proton Therapy Market for Pineal Parenchymal Tumor (Thousand US$), 2017 – 2021
Figure 6‑65: United States – Pediatric Proton Therapy Market for Esthesioneuroblastoma (Thousand US$), 2010 – 2016
Figure 6‑66: United States – Forecast for Esthesioneuroblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑67: United States – Pediatric Proton Therapy Market for Angiofibroma (Thousand US$), 2010 – 2016
Figure 6‑68: United States – Forecast for Angiofibroma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
Figure 6‑69: United States – Pediatric Proton Therapy Market for Extrarenal Rhabdoid Tumor (Thousand US$), 2010 – 2016
Figure 6‑70: United States – Forecast for Pediatric Proton Therapy Market by Extrarenal Rhabdoid Tumor (Thousand US$), 2017 – 2021
Figure 6‑71: United States – Pediatric Proton Therapy Market for Others (Thousand US$), 2010 – 2016
Figure 6‑72: United States – Forecast for Others Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021

Figure 7‑1: United States – Pediatric Proton Therapy Patients by Glioma, Low Grade (Number), 2010 – 2016
Figure 7‑2: United States – Forecast for Pediatric Proton Therapy Patients by Glioma, Low Grade (Number), 2017 – 2021
Figure 7‑3: United States – Pediatric Proton Therapy Patients by Glioma, High Grade (Number), 2010 – 2016
Figure 7‑4: United States – Forecast for Pediatric Proton Therapy Patients by Glioma, High Grade (Number), 2017 – 2021
Figure 7‑5: United States – Pediatric Proton Therapy Patients by Medulloblastoma (Number), 2010 – 2016
Figure 7‑6: United States – Forecast for Pediatric Proton Therapy Patients by Medulloblastoma (Number), 2017 – 2021
Figure 7‑7: United States – Pediatric Proton Therapy Patients by Ependymoma (Number), 2010 – 2016
Figure 7‑8: United States – Forecast for Pediatric Proton Therapy Patients by Ependymoma (Number), 2017 – 2021
Figure 7‑9: United States – Pediatric Proton Therapy Patients by ATRT (Number), 2010 – 2016
Figure 7‑10: United States – Forecast for Pediatric Proton Therapy Patients by ATRT (Number), 2017 – 2021
Figure 7‑11: United States – Pediatric Proton Therapy Patients by Germinoma, pure (Number), 2010 – 2016
Figure 7‑12: United States – Forecast for Pediatric Proton Therapy Patients by Germinoma, pure (Number), 2017 – 2021
Figure 7‑13: United States – Pediatric Proton Therapy Patients by Germ Cell Tumor (Number), 2010 – 2016
Figure 7‑14: United States – Forecast for Pediatric Proton Therapy Patients by Germ Cell Tumor (Number), 2017 – 2021
Figure 7‑15: United States – Pediatric Proton Therapy Patients by Craniopharyngioma (Number), 2010 – 2016
Figure 7‑16: United States – Forecast for Pediatric Proton Therapy Patients by Craniopharyngioma (Number), 2017 – 2021
Figure 7‑17: United States – Pediatric Proton Therapy Patients by PNET (Number), 2010 – 2016
Figure 7‑18: United States – Forecast for Pediatric Proton Therapy Patients by PNET (Number), 2017 – 2021
Figure 7‑19: United States – Pediatric Proton Therapy Patients by Pineoblastoma (Number), 2010 – 2016
Figure 7‑20: United States – Forecast for Pediatric Proton Therapy Patients by Pineoblastoma (Number), 2017 – 2021
Figure 7‑21: United States – Pediatric Proton Therapy Patients by Chordoma/Chondrosarcoma (Number), 2010 – 2016
Figure 7‑22: United States – Forecast for Pediatric Proton Therapy Patients by Chordoma/Chondrosarcoma (Number), 2017 – 2021
Figure 7‑23: United States – Pediatric Proton Therapy Patients by Meningioma (Number), 2010 – 2016
Figure 7‑24: United States – Forecast for Pediatric Proton Therapy Patients by Meningioma (Number), 2017 – 2021
Figure 7‑25: United States – Pediatric Proton Therapy Patients by AVM (Number), 2010 – 2016
Figure 7‑26: United States – Forecast for Pediatric Proton Therapy Patients by AVM (Number), 2017 – 2021
Figure 7‑27: United States – Pediatric Proton Therapy Patients by Adenoma (Number), 2010 – 2016
Figure 7‑28: United States – Forecast for Pediatric Proton Therapy Patients by Adenoma (Number), 2017 – 2021
Figure 7‑29: United States – Pediatric Proton Therapy Patients by Choroid Plexus Carcinoma (Number), 2010 – 2016
Figure 7‑30: United States – Forecast for Pediatric Proton Therapy Patients by Choroid Plexus Carcinoma (Number), 2017 – 2021
Figure 7‑31: United States – Pediatric Proton Therapy Patients by Retinoblastoma (Number), 2010 – 2016
Figure 7‑32: United States – Forecast for Pediatric Proton Therapy Patients by Retinoblastoma (Number), 2017 – 2021
Figure 7‑33: United States – Pediatric Proton Therapy Patients by Osteosarcoma (Number), 2010 – 2016
Figure 7‑34: United States – Forecast for Pediatric Proton Therapy Patients by Osteosarcoma (Number), 2017 – 2021
Figure 7‑35: United States – Pediatric Proton Therapy Patients by Ewing Sarcoma (Number), 2010 – 2016
Figure 7‑36: United States – Forecast for Pediatric Proton Therapy Patients by Ewing Sarcoma (Number), 2017 – 2021
Figure 7‑37: United States – Pediatric Proton Therapy Patients by Rhabdomyosarcoma (Number), 2010 – 2016
Figure 7‑38: United States – Forecast Pediatric Proton Therapy Patients by Rhabdomyosarcoma (Number), 2017 – 2021
Figure 7‑39: United States – Pediatric Proton Therapy Patients by Other Sarcoma, High Grade (Number), 2010 – 2016
Figure 7‑40: United States – Forecast for Pediatric Proton Therapy Patients by Other Sarcoma, High Grade (Number), 2017 – 2021
Figure 7‑41: United States – Pediatric Proton Therapy Patients by Other Sarcoma, Low Grade (Number), 2010 – 2016
Figure 7‑42: United States – Forecast for Pediatric Proton Therapy Patients by Other Sarcoma, Low Grade (Number), 2017 – 2021
Figure 7‑43: United States – Pediatric Proton Therapy Patients by Teratoma (Number), 2010 – 2016
Figure 7‑44: United States – Forecast for Pediatric Proton Therapy Patients by Teratoma (Number), 2017 – 2021
Figure 7‑45: United States – Pediatric Proton Therapy Patients by Neuroblastoma (Number), 2010 – 2016
Figure 7‑46: United States – Forecast for Pediatric Proton Therapy Patients by Neuroblastoma (Number), 2017 – 2021
Figure 7‑47: United States – Pediatric Proton Therapy Patients by Ganglioglioma (Number), 2010 – 2016
Figure 7‑48: United States – Forecast for Pediatric Proton Therapy Patients by Ganglioglioma (Number), 2017 – 2021
Figure 7‑49: United States – Pediatric Proton Therapy Patients by Wilm’s Tumor (Number), 2010 – 2016
Figure 7‑50: United States – Forecast for Pediatric Proton Therapy Patients by Wilm’s Tumor (Number), 2017 – 2021
Figure 7‑51: United States – Pediatric Proton Therapy Patients by Carcinoma (non-CPC) (Number), 2010 – 2016
Figure 7‑52: United States – Forecast for Pediatric Proton Therapy Patients by Carcinoma (non-CPC) (Number), 2017 – 2021
Figure 7‑53: United States – Pediatric Proton Therapy Patients by Lymphoma, Hodgkin’s (Number), 2010 – 2016
Figure 7‑54: United States – Forecast for Pediatric Proton Therapy Patients by Lymphoma, Hodgkin’s (Number), 2017 – 2021
Figure 7‑55: United States – Pediatric Proton Therapy Patients by Lymphoma, Non-hodgkin’s (Number), 2010 – 2016
Figure 7‑56: United States – Forecast for Pediatric Proton Therapy Patients by Lymphoma, Non-hodgkin’s (Number), 2010 – 2016
Figure 7‑57: United States – Pediatric Proton Therapy Patients by Leukemia (Number), 2010 – 2016
Figure 7‑58: United States – Forecast for Pediatric Proton Therapy Patients by Leukemia (Number), 2017 – 2021
Figure 7‑59: United States – Pediatric Proton Therapy Patients by Desmoid (Number), 2010 – 2016
Figure 7‑60: United States – Forecast for Pediatric Proton Therapy Patients by Desmoid (Number), 2017 – 2021
Figure 7‑61: United States – Pediatric Proton Therapy Patients by Melanoma (Number), 2010 – 2016
Figure 7‑62: United States – Forecast for Pediatric Proton Therapy Patients by Melanoma (Number), 2017 – 2021
Figure 7‑63: United States – Pediatric Proton Therapy Patients by Pineal Parenchymal Tumor (Number), 2010 – 2016
Figure 7‑64: United States – Forecast for Pediatric Proton Therapy Patients by Pineal Parenchymal Tumor (Number), 2017 – 2021
Figure 7‑65: United States – Pediatric Proton Therapy Patients by Esthesioneuroblastoma (Number), 2010 – 2016
Figure 7‑66: United States – Forecast for Pediatric Proton Therapy Patients by Esthesioneuroblastoma (Number), 2017 – 2021
Figure 7‑67: United States – Pediatric Proton Therapy Patients by Angiofibroma (Number), 2010 – 2016
Figure 7‑68: United States – Forecast for Pediatric Proton Therapy Patients by Angiofibroma (Number), 2017 – 2021
Figure 7‑69: United States – Pediatric Proton Therapy Patients by Extrarenal Rhabdoid Tumor (Number), 2010 – 2016
Figure 7‑70: United States – Forecast for Pediatric Proton Therapy Patients by Extrarenal Rhabdoid Tumor (Number), 2017 – 2021
Figure 7‑71: United States – Pediatric Proton Therapy Patients by Others (Number), 2010 – 2016
Figure 7‑72: United States – Forecast for Pediatric Proton Therapy Patients by Others (Number), 2017 – 2021

Figure 9‑1: United States – Pediatric Patient Diagnosed With Cancer (Number), 2010 – 2016
Figure 9‑2: United States – Forecast for Pediatric Patient Cancer Incidence (Number), 2017 – 2021

Figure 11‑1: Global – IBA Proton Therapy Sales (Million US$), 2010 – 2016
Figure 11‑2: Global – Forecast for IBA Proton Therapy Sales (Million US$), 2017 – 2021
Figure 11‑3: Global – Varian Medical Systems Oncology Systems Sales (Million US$), 2010 – 2016
Figure 11‑4: Global – Forecast for Varian Medical Systems Oncology Systems Sales (Million US$), 2017 – 2021
Figure 11‑5: Global – Mitsubishi Electric Corporation Energy and Electric Systems Sales (Million US$), 2010 – 2016
Figure 11‑6: Global – Forecast for Mitsubishi Electric Corporation Energy and Electric Systems Sales (Million US$), 2017 – 2021
Figure 11‑7: Global – Hitachi Electronic Systems and Equipment Sales (Million US$), 2010 – 2016
Figure 11‑8: Global – Forecast for Hitachi Electronic Systems and Equipment Sales (Million US$), 2017 – 2021
 

List of Tables

Table 11 1: Global – IBA Proton Therapy Centers in Operational and Under-Construction Phase    
Table 11 2: Global – Mitsubishi Proton Therapy Centers in Operational and Under-Construction Phase    
Table 11 3: Global – Hitachi Proton Therapy Centers in Operational and Under-Construction Phase